Open AccessPossibilities and limitations of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease
Author(s) -
И. В. Лещенко
Publication year - 2018
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2018-28-5-602-612
Subject(s) - medicine , copd , exacerbation , inhaled corticosteroids , pulmonary disease , pneumonia , adverse effect , inhalation , body mass index , intensive care medicine , asthma , anesthesia
Combinations of inhaled corticosteroids (ICS) and long-acting bronchodilators are recommended for those patients with chronic obstructive pulmonary disease (COPD) who did not improve significantly with regular long-acting bronchodilators. ICS are known to increase the risk of pneumonia in elderly patients (over 55 years), current smokers, patients with acute exacerbation of COPD, patients with history of previous pneumonia, patients with body mass index < 25 kg/m2, and patients with dyspnea or severe airflow limitation. The risk-benefit ratio should be considered before initiating the treatment with ICS in COPD patients, particularly in patients with the risk factors of adverse events associated with ICS.